Blood test can predict onset and track progression of Huntington's disease

June 7, 2017
A montage of three images of single striatal neurons transfected with a disease-associated version of huntingtin, the protein that causes Huntington's disease. Nuclei of untransfected neurons are seen in the background (blue). The neuron in the center (yellow) contains an abnormal intracellular accumulation of huntingtin called an inclusion body (orange). Credit: Wikipedia/ Creative Commons Attribution 3.0 Unported license

The first blood test that can predict the onset and progression of Huntington's disease has been identified by a UCL-led study.

The researchers say their findings, published in Lancet Neurology, should help new treatments for the genetic brain disorder, which is fatal and currently incurable.

"This is the first time a potential blood biomarker has been identified to track Huntington's disease so strongly," said the study's senior author, Dr Edward Wild (UCL Institute of Neurology).

The test measures the neurofilament light chain (neurofilament), a protein released from damaged brain cells, which has been linked to other neurodegenerative diseases but hasn't been studied in the blood of Huntington's disease (HD) patients before.

The team, led by scientists at UCL Huntington's Disease Centre working with colleagues in Sweden, the USA, Canada, France and the Netherlands, measured neurofilament levels in blood samples from the TRACK-HD study, an international project that followed 366 volunteers for three years. They found that levels of the brain protein were increased throughout the course of HD—even in carriers of the HD genetic mutation who were many years from showing symptoms of the disease. HD mutation carriers had neurofilament concentrations that were 2.6 times that of the control participants, and the level rose throughout the disease course from premanifest to stage 2 disease.

In the group who had no symptoms at the start of the study, the level of neurofilament predicted subsequent disease onset, as volunteers with high neurofilament levels in the blood at the start were more likely to develop symptoms in the following three years. After taking into account factors already known to predict progression—age and a genetic marker—the blood level of neurofilament was still able to independently predict onset, progression and the rate of brain shrinkage as measured by MRI scans.

Currently, the best biomarkers available are measured with neuroimaging or cerebrospinal fluid, which are more difficult and expensive to obtain than a . The researchers say that predicting progression in mutation carriers who do not yet show symptoms has been particularly challenging.

"We have been trying to identify blood biomarkers to help track the progression of HD for well over a decade, and this is the best candidate that we have seen so far," said Dr Wild. "Neurofilament has the potential to serve as a speedometer in Huntington's disease, since a single blood test reflects how quickly the brain is changing. That could be very helpful right now as we are testing a new generation of so-called 'gene silencing' drugs that we hope will put the brakes on the condition. Measuring neurofilament levels could help us figure out whether those brakes are working."

The researchers caution that the test is not expected to be immediately helpful for individual patients. "This is the first time neurofilament has been measured in , so much more work is needed to understand the potential and limitations of this test," said Lauren Byrne (UCL Institute of Neurology), the study's first author. "In the future, if drugs to slow HD become available, it may well be used to guide treatment decisions. For now, this test is most promising as a much-needed tool to help us design and run clinical trials of new drugs."

Dr Robert Pacifici, chief scientific officer of CHDI Foundation, a US non-profit Huntington's research foundation, welcomed the development. "I can see neurofilament becoming a valuable tool to assess neuroprotection in clinical trials so that we can more quickly figure out whether new drugs are doing what we need them to. As a drug hunter, this is great news."

The study's funders included the CHDI foundation, GlaxoSmithKline, Swedish Research Council, European Research Council, Wallenberg Foundation and Wolfson Foundation.

Explore further: A new biomarker for nerve cell damage

More information: Lancet Neurology (2017). DOI: 10.1016/S1474-4422(17)30124-2

Related Stories

A new biomarker for nerve cell damage

June 9, 2016
Scientists at the German Center for Neurodegenerative Diseases, the Hertie Institute for Clinical Brain Research and the University of Tübingen have identified proteins in the blood and cerebrospinal fluid that reflect nerve ...

Blood test may help differentiate Parkinson's from similar diseases

February 8, 2017
A simple blood test may be as accurate as a spinal fluid test when trying to determine whether symptoms are caused by Parkinson's disease or another atypical parkinsonism disorder, according to a new study published in the ...

Researchers track Huntington's disease progression using PET scans

August 29, 2013
Investigators at The Feinstein Institute for Medical Research have discovered a new way to measure the progression of Huntington's disease, using positron emission tomography (PET) to scan the brains of carriers of the gene. ...

Protein test is first to predict rate of progression in Lou Gehrig's disease

November 19, 2012
(Medical Xpress)—A novel test that measures proteins from nerve damage that are deposited in blood and spinal fluid reveals the rate of progression of amyotrophic lateral sclerosis (ALS) in patients, according to researchers ...

New test measures deadly protein in Huntington's disease patients' spinal fluid

April 6, 2015
A new test has been able to measure for the first time the build-up of a harmful mutant protein in the nervous system of patients during the progression of Huntington's disease (HD). Published today in the Journal of Clinical ...

Recommended for you

Offbeat brain rhythms during sleep make older adults forget

December 15, 2017
Like swinging a tennis racket during a ball toss to serve an ace, slow and speedy brainwaves during deep sleep must sync up at exactly the right moment to hit the save button on new memories, according to new UC Berkeley ...

Study finds graspable objects grab attention more than images of objects do

December 15, 2017
Does having the potential to act upon an object have a unique influence on behavior and brain responses to the object? That is the question Jacqueline Snow, assistant professor of psychology at the University of Nevada, Reno, ...

Little understood cell helps mice see color

December 14, 2017
Researchers at the University of Colorado Anschutz Medical Campus have discovered that color vision in mice is far more complex than originally thought, opening the door to experiments that could potentially lead to new treatments ...

Scientists chart how brain signals connect to neurons

December 14, 2017
Scientists at Johns Hopkins have used supercomputers to create an atomic scale map that tracks how the signaling chemical glutamate binds to a neuron in the brain. The findings, say the scientists, shed light on the dynamic ...

Journaling inspires altruism through an attitude of gratitude

December 14, 2017
Gratitude does more than help maintain good health. New research at the University of Oregon finds that regularly noting feelings of gratitude in a journal leads to increased altruism.

Activating MSc glutamatergic neurons found to cause mice to eat less

December 13, 2017
(Medical Xpress)—A trio of researchers working at the State University of New York has found that artificially stimulating neurons that exist in the medial septal complex in mouse brains caused test mice to eat less. In ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.